|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3 Pt 1
|
|
pubmed:dateCreated |
1999-10-7
|
|
pubmed:abstractText |
To evaluate the costs and benefits of two new agents, respiratory syncytial virus immune globulin (RSVIG) and palivizumab, to prevent respiratory syncytial virus (RSV) infection among premature infants discharged from the neonatal intensive care unit (NICU) before the start of the RSV season. Method. Decision analysis was used to compare the projected societal cost-effectiveness of three strategies-RSVIG, palivizumab, and no prophylaxis-among a hypothetical cohort of premature infants. Probabilities and costs of hospitalization were derived from a cohort of 1721 premature infants discharged from six Kaiser Permanente-Northern California NICUs. Efficacies of prophylaxis were based on published trials. Costs of prophylaxis were derived from published sources. Mortality among infants hospitalized for RSV was assumed to be 1.2%. Future benefits were discounted at 3%.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0031-4005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
419-27
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10469764-Antibodies, Monoclonal,
pubmed-meshheading:10469764-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:10469764-Cost of Illness,
pubmed-meshheading:10469764-Cost-Benefit Analysis,
pubmed-meshheading:10469764-Decision Support Techniques,
pubmed-meshheading:10469764-Drug Costs,
pubmed-meshheading:10469764-Hospital Costs,
pubmed-meshheading:10469764-Hospitalization,
pubmed-meshheading:10469764-Humans,
pubmed-meshheading:10469764-Immunoglobulins, Intravenous,
pubmed-meshheading:10469764-Infant, Newborn,
pubmed-meshheading:10469764-Infant, Premature,
pubmed-meshheading:10469764-Infant, Premature, Diseases,
pubmed-meshheading:10469764-Respiratory Syncytial Virus Infections,
pubmed-meshheading:10469764-Respiratory Syncytial Viruses,
pubmed-meshheading:10469764-Risk Factors
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
|
|
pubmed:affiliation |
Division of Pediatric Hematology/Oncology, Children's Hospital, and the Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
|
|
pubmed:publicationType |
Journal Article
|
